Bioequivalence of DWJ1558 vs Co-administered DWC202310 and DWC202311 in Healthy Volunteers

Phase 1, randomised, open-label trial of DWJ1558 in essential hypertension and hypercholesterolemia (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at Steady State at 72 hours and Area Under the Concentration-Time Curve from Time 0 to Last Measurable Concentration at 72 hours. Status: unknown.